Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine as adjunctive therapy for major depression
NCT04939649Phase 3Completed
- Sponsor
- Trinity College Dublin
- Start
- Sep 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine in major depressive disorder (MDD) and bipolar disorder (BD), sponsored by Trinity College Dublin. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 28 weeks. Started Sep 2021; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT04939649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939649.